NCT00803569 2023-10-04
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Ludwig Institute for Cancer Research
Phase 1 Completed
Clinical Trials
8 trialsNCT00003002 2019-02-27
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
University of Washington
Phase 1 Completed
NCT00005023 2017-11-30
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
University of Washington
Phase 1 Completed
NCT00157573 2017-05-08
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT02470559 2016-02-17
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT00091273 2014-06-20
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
University of Virginia
Phase 1 Completed
NCT00501644 2012-08-07
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003269 2011-01-10
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
Scripps Health
Phase 2 Completed